Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015674 (chronic fatigue syndrome)
 2,978 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A prospective randomized study was conducted to determine the optimal schedule of rhG-CSF (recombinant human granulocyte colony-stimulating factor). A group of 33 lung cancer patients treated with MVP therapy (mitomycin, vindesine, and cisplatin) were randomly assigned to three groups: an early prophylaxis group in which rhG-CSF was initiated on day 2 of the MVP cycle; a late prophylaxis group in which rhG-CSF was initiated on day 8; and a therapeutic group in which rhG-CFS was initiated after the onset of neutropenia. Ten patients who had received MVP therapy without rhG-CSF were also analyzed as a no-support group. The incidence of neutropenia was 80% (16/20 courses) in the early prophylaxis group, 44% (8/18) in the late prophylaxis group, 94% (17/18) in the therapeutic group, and 94% (16/17) in the no-support group. The incidence of neutropenia in the late prophylaxis group was less than in the early prophylaxis group (P<0.05), the therapeutic group (P<0.01), and the no-support group (P<0.01). The late prophylactic rhG-CSF schedule was therefore more effective in countering neutropenia than either the early prophylactic or therapeutic schedule.
 ...
PMID:Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. 860 58

SRL 172, a protein derived from a soil-based organism, is advertised for being able to restart the immune systems of persons with allergies, lung cancer, and tuberculosis. SRL 172 also appears to shift the cytokine profile in persons with Gulf War Syndrome and Chronic Fatigue Syndrome from TH2 back to the more effective TH1 profile. One patient reports improved DTH skin responses to topical DNCB after using Nature's Biotics Soil-based Organisms (SBOs). There also appeared to be improved immunity response indicating a shift from a weaker TH2 to a TH1 cytokine profile. The patient explains his successful use of SBOs and reveals that all but 1 out of 100 other patients who have used the product for a variety of ailments cite successful outcomes. Among the ailments whose symptoms the SBOs have helped relieve are foot sores from diabetes, Chronic Fatigue Syndrome, insomnia, and genital herpes. Recent use of SBOs by HIV-infected patients has had positive results in energy and weight gain and improvements in some types of chronic conditions indicating an improvement of cell mediated immunity and antibody production.
 ...
PMID:Soil-based organisms improve immune function: shift cytokine profile from TH2 to TH1. 1136 13

Although it has been indicated that patients with lung cancer experience higher level of fatigue than patients with other cancers, few published studies have focused on the characteristics of this fatigue and how it interferes with daily activities. The purpose of this study was to clarify fatigue prevalence and the factors correlated with fatigue, and to develop a screening method for fatigue in patients with advanced lung cancer. One hundred fifty-seven patients completed two fatigue scales (Cancer Fatigue Scale [CFS], and Fatigue Numerical Scale [FNS]) plus other measures, along with a self-administered questionnaire asking whether fatigue had interfered with any of 7 areas of daily activities. Fifty-nine percent of patients had experienced clinical fatigue, which was defined as fatigue that interfered with any daily activities. Logistic regression analysis demonstrated that symptoms of dyspnea on walking, appetite loss, and depression were significant correlated factors. Both CFS and FNS were found to have sufficient sensitivity and specificity for use as a screening tool. The results indicated that fatigue is a frequent and important symptom, which is associated with both physical and psychological distress in this population. The CFS and FNS were confirmed to have sufficient screening ability.
 ...
PMID:Fatigue in ambulatory patients with advanced lung cancer: prevalence, correlated factors, and screening. 1151 97